Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma

por Früh, M, Zhou, W, Zhai, R, Su, L, Heist, R S, Wain, J C, Nishioka, N S, Lynch, T J, Shepherd, F A, Christiani, D C, Liu, G
Publicado 2008

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study

por Mark, M., Rusakiewicz, S., Früh, M., Hayoz, S., Grosso, F., Pless, M., Zucali, P., Ceresoli, G.L., Maconi, A., Schneider, M., Froesch, P., Tarussio, D., Benedetti, F., Dagher, J., Kandalaft, L., von Moos, R., Tissot-Renaud, S., Schmid, S., Metaxas, Y.
Publicado 2022

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

por König, D., Schär, S., Vuong, D., Guckenberger, M., Furrer, K., Opitz, I., Weder, W., Rothschild, S.I., Ochsenbein, A., Zippelius, A., Addeo, A., Mark, M., Eboulet, E.I., Hayoz, S., Thierstein, S., Betticher, D.C., Ris, H.-B., Stupp, R., Curioni-Fontecedro, A., Peters, S., Pless, M., Früh, M.
Publicado 2022

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/0...

por König, D., Savic Prince, S., Hayoz, S., Zens, P., Berezowska, S., Jochum, W., Stauffer, E., Braunersreuther, V., Trachsel, B., Thierstein, S., Mark, M., Schmid, S., Curioni-Fontecedro, A., Addeo, A., Opitz, I., Guckenberger, M., Früh, M., Betticher, D.C., Ris, H.-B., Stupp, R., Rothschild, S.I., Bubendorf, L., Pless, M.
Publicado 2023

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

por Dafni, U., Soo, R.A., Peters, S., Tsourti, Z., Zygoura, P., Vervita, K., Han, J.-Y., De Castro, J., Coate, L., Früh, M., Hashemi, S.M.S., Nadal, E., Carcereny, E., Sala, M.A., Bernabé, R., Provencio, M., Cuffe, S., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A.
Publicado 2022

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

por Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.
Publicado 2019